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Yok-Lam Kwong1 and Eric Tse1*Abstract
Background: The therapeutic efficacy of arsenic trioxide (As2O3) in acute myeloid leukemia (AML) is modest, which
is partly related to its limited intracellular uptake into the leukemic cells. As2O3 enters cells via the transmembrane
protein aquaglyceroporin 9 (AQP9). Azacytidine, a demethylating agent that is approved for the treatment of AML,
has been shown to have synergistic effect with As2O3. We tested the hypothesis that azacytidine might up-regulate
AQP9 and enhances As2O3-mediated cytotoxicity in AML.
Methods: Arsenic-induced cytotoxicity, the expression of AQP9, and the intracellular uptake of As2O3 were determined
in AML cell lines and primary AML cells with or without azacytidine pre-treatment. The mechanism of AQP9
up-regulation was then investigated by examining the expression of transcription factors for AQP9 gene and
the methylation status of their gene promoters.
Results: As2O3-induced cytotoxicity in AML cell lines was significantly enhanced after azacytidine pre-treatment as
a result of AQP9 up-regulation, leading to increased arsenic uptake and hence intracellular concentration. Blocking
AQP9-mediated As2O3 uptake with mercury chloride abrogated the sensitization effect of azacytidine. AQP9 promoter
does not contain CpG islands. Instead, azacytidine pre-treatment led to increased expression of HNF1A, a transcription
activator of AQP9, through demethylation of HNF1A promoter. HNF1 knockdown abrogated azacytidine-induced
AQP9 up-regulation and almost completely blocked intracellular As2O3 entry, confirming that azacytidine enhanced
As2O3-mediated cell death via up-regulation of HNF1A and hence increased AQP9 and As2O3 intracellular
concentration. Azacytidine sensitization to As2O3 treatment was re-capitulated also in primary AML samples. Finally,
azacytidine did not enhance arsenic toxicity in a liver cell line, where HNF1A was largely unmethylated.
Conclusions: Azacytidine sensitizes AML cells to As2O3 treatment, and our results provide proof-of-principle evidence
that pharmacological up-regulation of AQP9 potentially expands the therapeutic spectrum of As2O3. Further clinical trial
should evaluate the efficacy of azacytidine in combination with As2O3 in the treatment of AML.
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Arsenic trioxide (As2O3) is an important and highly effi-
cacious drug in the management of acute promyelocytic
leukemia (APL) [1,2]. It was first successfully used as a sal-
vage therapy for relapsed APL [3]. More recently, As2O3
has also been shown to be effective as first line induction
therapy in newly diagnosed APL [4,5] and as a mainten-
ance therapy [6]. The unique sensitivity of APL cells to
As2O3 is likely to be related to As2O3-mediated degrad-
ation of the PML-RARA chimeric protein, which is
an oncogenic protein produced as a result of the spe-
cific chromosomal translocation t(15;17)(q22;q12) [7,8].
In addition, As2O3 has also been shown to induce apop-
tosis through the generation of superoxides and reactive
oxygen species [9,10], disruption of the mitochondrial
transmembrane potential with release of cytochrome c
and caspase activation [11], and inhibition of DNA meth-
yltransferase DNMT leading to demethylation of tumor
suppressor genes [12].
Because As2O3 must enter cells before exerting its
cytotoxic activity, the control of arsenic trafficking through
the plasma membrane could conceivably modulate arsenic
sensitivity. Aquaglyceroporin 9 (AQP9) is a transmem-
brane solute transporting protein and is expressed in hu-
man leukocytes, liver, lung, and spleen [13]. Unlike the
typical aquaporin water channel, it also facilitates the pas-
sage of glycerol and many other non-charged solutes. We
and others have shown that AQP9 controls the transmem-
brane transport of As2O3, thereby playing a critical role in
determining the sensitivity of cells towards As2O3-induced
cytotoxicity [14,15]. In myeloid leukemia cells, expression
levels of AQP9 are directly proportional to intracellu-
lar arsenic concentrations upon As2O3 treatment, which
translate into increased arsenic sensitivity [14]. Of the dif-
ferent subtypes of acute myeloid leukemia (AML), APL
cells express the highest concentration of AQP9, which
might in part explain their exquisite sensitivity to
As2O3 [14]. Furthermore, all-trans retinoic acid (ATRA)
up-regulates AQP9 expression, contributing to its synergis-
tic cytotoxic effect with As2O3 [14]. However, the regula-
tion of AQP9 expression remains unclear. Understanding
the mechanisms controlling AQP9 expression may enable
pharmacological strategies to be designed to up-regulate
AQP9 in leukemia cells, hence constituting a potential
method to expand the therapeutic spectrum of As2O3 in
the treatment of AML.
Demethylating agents, including azacitidine and deci-
tabine, are a standard medication for the management of
myelodysplastic syndrome and elderly subjects with
AML [16-19]. Recently, demethylating agents have been
shown to synergize with As2O3 in the treatment of AML
in vitro and in vivo [20,21]. However, the biological basis
of the synergism between demethylating agents and
As2O3 has not been defined.In this study, we proposed that one of the mechanisms
of synergism between demethylating agents and As2O3
might be through modulation of AQP9 expression. To
test this hypothesis, we examined the effect of azacyti-
dine treatment on AQP9 expression and plasma mem-
brane arsenic trafficking in AML cell lines and primary
AML samples.
Materials and methods
Cells and reagents
The human myeloid leukemia cell lines HL-60 and K562
(purchased from ATCC, Manassas, VA, USA) and the
APL cell line NB4 (a kind gift from Dr. Shen ZX, Shanghai
Institute of Hematology, Rui Jin Hospital, Shanghai, China)
were cultured in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin in
5% CO2 at 37°C. They have been characterized and
tested as described previously [14]. The human leukemia
line OCI-AML3 (purchased from DSMZ, Braunschweig,
Germany) was cultured in α-MEM with 20% FBS in simi-
lar conditions. The immortalized human liver cell line
MIHA (a kind gift from Dr. J Roy-Chowdhury, Albert
Einstein College of Medicine, New York, USA) was
cultured in DMEM with 10% FBS. MIHA has been char-
acterized and tested as described previously [22]. Primary
AML samples from peripheral blood (PB) and/or bone
marrow (BM) were obtained with informed consent from
patients treated at Queen Mary Hospital, Hong Kong. Pri-
mary cells were cultured in StemSpan H3000 supple-
mented with StemSpan CC100 cytokine cocktail (StemCell
Technologies, Vancouver, Canada). Archival samples were
obtained from marrow mononuclear cells of AML pa-
tients stored at −80°C. Procurement of these samples
was approved by the institute review board according
to the Declaration of Helsinki. The demethylating drug
azacytidine (5-aza-2′deoxycytidine; 5′Aza) and As2O3
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
The polyclonal phycoerythrin (PE)-conjugated anti-AQP9
and PE-conjugated isotypic control antibodies were pur-
chased from Bioss Antibodies (Bioss Inc., Woburn, MA,
USA).
As2O3 cytotoxicity
Cells pre-treated with or without azacytidine (5 μM for
3 days) were washed twice with phosphate-buffered saline
(PBS), re-suspended in fresh RPMI-1640 supplemented
with 10% FBS, and treated with various concentration of
As2O3 (0.0, 0.3125, and 0.625 μM for NB4; 0.0, 2.5, 5.0,
and 10.0 μM in other cells). For experiments where AQP9
blockade was involved, cells were incubated in addition
with mercury chloride (HgCl2) at 10 μM for 2 hours.
For 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide (MTT) assay, 100 μL of each cell suspension was
incubated for 48 hours in 96-well plates, followed by the
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solubilizing buffer (100 μL overnight), and absorbance
measurement at 560 nm. All experiments were performed
in triplicates.Flow cytometric analysis
For apoptosis assay, cells treated with or without azacyti-
dine were analyzed for apoptotic cells using a Cytomics
FC 500 flow cytometer (Beckman Coulter, Brea, CA,
USA), using an annexin V: phycoerythrin and 7-AAD
apoptosis detection kit (BD Biosciences, San Jose, CA,
USA). Cells were incubated with respective antibodies
for 15 min and subjected to flow cytometric analysis. At
least 10,000 events were collected. All flow cytometry
plots and data were acquired from at least three inde-
pendent experiments.Quantification of gene expression
Total RNA was extracted using Trizol reagent (Life tech-
nologies, Carlsbad, CA, USA), and 1 μg of RNA was re-
versely transcribed (SuperScript III First Strand Synthesis
system, Life technologies, Carlsbad, CA, USA). The resulting
cDNAs were used for semi-quantitative reverse transcription
polymerase chain reaction (RT-PCR) or quantitative RT-PCR
(q-RT-PCR). Primers for quantification of target and con-
trol genes were designed by the Primer Express software
(Applied Biosystems, Life technologies, Carlsbad, CA, USA)
(primer sequences and reaction conditions were listed
in Additional file 1). Quantitative RT-PCR was per-
formed using Power SYBR Green PCR Master Mix (Applied
Biosystems, Carlsbad, CA, USA) and a StepOnePlus Real
Time PCR system (Applied Biosystems, Carlsbad, CA,
USA). The expressions of target genes with respect to the
internal control gene were analyzed with the comparative
CT (ΔΔCT) method. Experiments were performed in
triplicates.Western immunoblotting
Cells were washed twice with PBS and were then lysed
in RIPA buffer [RIPA: 50 mM of Tris-HCl buffer pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, and 0.25%
(w/v) sodium deoxycholate, with the addition of a protease
inhibitor cocktail (Roche Diagnostic, Sulzfeld, Germany),
1 mM phenylmethylsulfonyl fluoride (PMSF)]. Total pro-
tein concentration was determined using the BCA protein
assay kit (Pierce Biotechnology, Rockford, IL, USA) ac-
cording to the manufacturer’s instructions. For Western
blot analysis, antibodies against HNF1A (Cell Signaling,
Danvers, MA, USA) and β-actin (Sigma, St. Louis,
MO, USA) were used. For detection of bound antibodies,
HRP-conjugated secondary antibodies were used (Life
Technologies (Carlsbad, CA, USA)).RNA interference and transfection
Gene knockdown experiments were performed with
siRNA (sequences of siRNA in Additional file 1), with
negative controls (AllStars Negative Controls, Qiagen,
Venlo, Netherlands). K562 cells (2 × 105 cells in 100 μL)
were transfected with siRNA (200 ng diluted in RPMI-
1640 medium, incubated at room temperature for 10
min with 6 μL HiPerfect transfection reagent, Qiagen,
Germantown, MD, USA) for 6 h in 5% CO2 at 37°C,
after which 600 μL of medium with FBS and antibi-
otics was added, followed by another 72 h of incuba-
tion before analysis. Experiments were performed in
triplicates.
Measurement of intracellular arsenic concentration
Cells were harvested, washed twice in ice-cold PBS, pel-
leted, and lysed in 0.9 mL of double-distilled water by
sonication for 10 min. Yttrium (Chem Service, West
Chester, PA, USA) dissolved in 2% nitric acid to ten parts
per billion was then added as an internal standard to the
lysate, which was vortexed and centrifuged at 3000 × g for
10 min. The supernatant was collected and assayed for
arsenic concentration by inductively coupled plasma-
mass spectrometry [23]. Experiments were performed
in triplicates.
Bisulfite modification of DNA, methylation-specific PCR
and combined bisulfite restriction analysis
Genomic DNA was isolated with the QIAamp DNA
Blood Mini Kit (Qiagen, Germantown, MD, USA). Bisul-
fite modification of DNA was performed with the Zymo
DNA modification kit (Zymo Research, Irvine, CA, USA).
Methylation-specific PCR (MSP) specific primers for the
methylated and unmethylated alleles were designed using
the OLIGO 6 primer analysis software (Molecular Biology
Insights, Cascade, CO, USA) (primer sequences in Additional
file 1: Supplementary Information), and the PCR products
were analyzed by gel electrophoresis. CpGenome universal
methylated DNA (Chemicon International Inc, Billerica,
MA, USA) was used as a positive control. For combined
bisulfite restriction analysis (COBRA), bisulfite-modified
DNA before and after treatment was amplified by PCR
with primers spanning the CG-rich region of target
gene promoter (primer sequences in Additional file 1:
Supplementary Information) and digested with the restric-
tion endonuclease BstUI (New England Biolabs, Ipswich,
MA, USA). PCR products were analyzed by gel electro-
phoresis to determine the respective methylation status.
Statistical analysis
Comparative analysis of cell viability and AQP9 expres-
sion were performed by the Student’s t-test, whereas cor-
relation analysis on AQP9 and HNF1A expression was
performed using the Pearson’s χ2-test. All values were
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were considered statistically significant when p value
was <0.05.
Results
Azacytidine sensitized leukemia cells to As2O3-induced
cytotoxicity
Of the four leukemia cell lines tested, NB4 showed the
highest sensitivity to As2O3, whereas HL-60, K562, and
OCI-AML3 had comparable sensitivities. Pre-treatment
with azacytidine significantly sensitized these cells to
As2O3-induced cytotoxicity (Figure 1A). Similar results
were obtained with the annexin V/7-AAD apoptosis
assay (Figure 1B,C).0.00
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Figure 1 Sensitization of leukemia cells to As2O3-induced cytotoxicity with
As2O3 with or without 5′Aza treatment in the human AML cell lines, HL-60
lines pre-treated with 5′Aza exhibited significant decrease in cell viability a
three independent experiments, and relative survival of each individual cel
of flow cytometric analysis, showing a significant increase in As2O3-mediate
with 5′Aza, as compared with control cells not treated with 5′Aza. (C) Bar c
V-positive cells) in each AML lines with or without 5′Aza pre-treatment. Qu
increase in As2O3-induced apoptotic cell death after 5′Aza pre-treatment.Azacytidine increased AQP9 level and enhanced
intracellular entry of As2O3
RT-PCR showed that azacytidine treatment significantly
increased AQP9 gene expression (Figure 2A, upper panel).
Quantitative RT-PCR confirmed a four- to fivefold in-
crease in AQP9 mRNA upon azacytidine treatment
(Figure 2A, lower panel). Flow cytometric analysis showed
a corresponding increase in surface expression of AQP9
(Figure 2B). The azacytidine-induced increase in AQP9
expression was functional, as it resulted in enhanced ar-
senic entry into cells (Figure 2C). To verify that AQP9 ac-
tually mediated increased arsenic entry into cells, which
then led to cytotoxicity, the effect of AQP9 blockade with
HgCl2 was examined [24]. As shown in Figure 2D (left0.00
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Figure 2 Azacytidine-mediated up-regulation of AQP9 expression and intracellular arsenic uptake. (A) AQP9 mRNA expression was significantly
up-regulated with 5′Aza treatment in HL-60, K562, NB4, and OCI-AML3 cells, as determined by RT-PCR (upper panel) and quantitative RT-PCR
(lower panel). Sample data were normalized to the control of each cell line individually by the ΔΔCT method. (B) Up-regulation of membrane
AQP9 protein expression was also confirmed by flow cytometric analysis. (C) Intracellular elemental arsenic concentration is significantly increased
in K562 cells after pre-treatment with 5′Aza. (D) Treatment of K562 cells with HgCl2 completely abrogated the cytotoxicity induced by As2O3,
either alone (left panel) or in cells pre-treatment with 5′Aza (right panel).
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Figure 3 Quantitative RT-PCR analysis of the expression of potential
transcription factors for the AQP9 gene after 5′Aza treatment in HL-60
and K562 cells. The expressions of five transcription factors, including
HNF1A, CEBPα, CEBPγ, NF-1, and JUN, with or without 5′Aza treatment
in HL-60 and K562 cells, were determined by quantitative RT-PCR.
Sample data were normalized to the control gene GAPDH for
each cell line individually.
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duced by As2O3. More importantly, HgCl2 treatment also
abolished the sensitization to As2O3 resulting from pre-
treatment with azacytidine (Figure 2D, right panel). These
results illustrated that azacytidine sensitized cells to As2O3
by increasing AQP9 expression, leading to increased ar-
senic entry and therefore enhanced cytotoxicity on subse-
quent exposure to As2O3.
Transcription factor HNF1A was up-regulated by
azacytidine treatment
A thorough analysis of the DNA sequence of the AQP9
promoter did not show any CpG islands, implying that
up-regulation of AQP9 with azacytidine is not due to
AQP9 promoter demethylation. Examination of the AQP9
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Figure 4 (See legend on next page.)
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Figure 4 Transcription factor HNF1A was involved in azacytidine-induced up-regulation of AQP9. (A). HNF1A mRNA and protein expressions
were markedly up-regulated after treatment of 5′Aza as examined by semi-quantitative and quantitative RT-PCR (upper panel) and western
immunoblotting (lower panel). (B) Diagram depicting the regions of the HNF1A promoter analyzed by Methylation-specific PCR (MSP) and Combined
Bisulfite Restriction Analysis (COBRA). (C) The methylation status of HNF1A gene promoter was extensively studied and determined using combined
bisulfite restriction analysis. 5′Aza treatment resulted in demethylation of the HNF1A gene promoter. (C: control; IVD: universal methylated DNA).
(D) Methylation-specific PCR (MSP) was performed using PCR primers specific for methylated or unmethylated HNF1A gene promoter. The
results showed that the HNF1A gene promoter was highly methylated, and 5′Aza treatment led to demethylation of the HNF1A gene promoter.
(E) Specific HNF1A siRNA abrogated 5′Aza-induced AQP9 up-regulation as determined by RT-PCR (upper panel) and quantitative RT-PCR (lower panel).
(F) In K562 cells treated with 5′Aza, specific HNF1A siRNA almost completely blocked the intracellular entry of As2O3 as compared with the control
siRNA-treated cells. The results showed that HNF1A was the mediator for up-regulation of AQP9 after 5′Aza treatment.
Chau et al. Journal of Hematology & Oncology  (2015) 8:46 Page 7 of 11promoter via the online database (UCSC Genome Browser
on Human Mar. 2006 (NCBI/hg18) Assembly) and pub-
lished literature showed putative DNA binding sites for
several transcription factors, including hepatic nuclear
factor 1A (HNF1A), CCAAT/enhancer-binding protein α
(C/EBPα), C/EBPγ, c-JUN, and NF-κB [13]. Quantitative
RT-PCR showed that HNF1A was the most significantly
and consistently up-regulated transcription factor after
azacytidine treatment (Figure 3).
Promoter methylation of HNF1A impacted on AQP9
expression and hence transmembrane arsenic
trafficking
HL-60 and K562 cells expressed very low levels of HNF1A,
whereas NB4 cells had a slightly higher basal HNF1A ex-
pression (Figure 4A). Treatment with azacytidine led to aPatients
1  2 6 7 8 9 10  13 4 5 11 12
p = 0.0045
A
B
Figure 5 Methylation status of HNF1A promoter and correlation between t
showing highly methylated HNF1A promoter in 16 human AML samples. (B
samples. Result was analyzed using Pearson test. AQP9 level was found tomarked increase in HNF1A mRNA and protein expres-
sion in all three leukemia lines (Figure 4A). The HNF1A
promoter contains a stretch of CpG islands (Figure 4B).
With COBRA, the HNF1A promoter was found to be
highly methylated in all three AML cell lines, and treat-
ment with azacytidine led to demethylation of the HNF1A
promoter (Figure 4C). The COBRA findings were repli-
cated in MSP analysis (Figure 4D). To show that azacyti-
dine treatment leading to promoter demethylation and
re-expression of HNF1A was biologically relevant, siRNA
was used to knock-down HNF1A. As shown in Figure 4E,
K562 cells treated with azacytidine showed considerable
up-regulation of HNF1A and hence AQP9, which was sig-
nificantly suppressed with HNF1A siRNA. This resulted
in an almost complete blockade of arsenic entry into K562
cells (Figure 4F).Methylated
Unmethylated
HNF1A
K562
3 14 15 16 C      5’Aza
he expressions of AQP9 and HNF1A in primary AML samples. (A) MSP
) Quantification of AQP9 and HNF1A expressions in 16 human AML
correlate positively with HNF1A level (p = 0.0045).
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In an archival panel of 16 non-APL AML cells, MSP
showed that HNF1A promoter was highly methylated
(Figure 5A). On quantitative RT-PCR, expressions of
HNF1A and AQP9 were positively correlated, confirm-
ing that HFN1A was an important transcription activa-
tor of the AQP9 gene in AML (Figure 5B).
Azacytidine increased AQP9 level and enhanced
As2O3-mediated cytotoxicity in primary human AML cells
Circulating AML blasts from seven patients with non-
APL AML were examined. Treatment with azacytidine
led to a significant increase in HNF1A and AQP9 expres-
sion (Figure 6A). Furthermore, pre-treatment with aza-
cytidine significantly sensitized AML cells to subsequent
As2O3 treatment in all cases (Figure 6B).
Azacytidine pre-treatment and subsequent As2O3 treatment
did not lead to enhanced cytotoxicity in human liver cell line
One of the major toxicities of As2O3 treatment is liver
damage, so it is important to determine if azacytidineA
B
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significant up-regulation of HNF1A (left panel) and AQP9 (right panel) as d
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patient individually. Results represented triplicates of seven samples of primtreatment might exacerbate hepatotoxicity. In the primary
liver cell line MIHA [22], basal AQP9 expression was
much higher than that of the AML cell lines (Figure 7A).
Treatment with azacytidine did not significantly in-
crease AQP9 expression (Figure 7B). MSP showed that
the HNF1A promoter was almost totally unmethylated in
MIHA cells, and expectedly treatment with azacytidine
did not lead to a significant increase in HNF1A expression
(Figure 7C). Finally, pre-treatment of MIHA cells with
azacytidine did not enhance the cytotoxicity of subsequent
As2O3 treatment (Figure 7D).
Discussion
With the use of ATRA and chemotherapy, complete re-
mission (CR) rates of over 90% can be achieved in newly
diagnosed APL. In relapsed APL, As2O3 has been shown
to be a highly effective salvage therapy [3]. Combination
therapy with As2O3 and ATRA as frontline treatment
for APL also results a very high CR rate and improved
long-term outcomes [4,5]. We have also shown that the
use of As2O3 and ATRA as maintenance therapy is safe
and may decrease relapse in APL patients in first CR [6].** p < 0.0001
n = 7
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those of AML cells. (B) 5′Aza treatment did not increase AQP9 expression significantly in MIHA. (C) HNF1A promoter was hypomethylated in
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underlying the synergistic interaction between As2O3 and
ATRA might be ATRA-mediated up-regulation of AQP9,
resulting in increased cellular uptake and hence intracellu-
lar concentrations of arsenic [14].
In this study, we tested the hypothesis that AQP9 might
be involved in the observed synergistic interaction of
azacytidine with As2O3. Because we wanted to minimize
the cytotoxic action of azacytidine as a confounding factor
in our experiments, azacytidine was used only as a pre-
treatment and removed from the culture system during
subsequent As2O3 treatment. In this way, we showed
that azacytidine pre-treatment sensitized cells to As2O3-
induced cytotoxicity.Our data clearly showed that azacytidine up-regulated
AQP9 through demethylation of the promoter and there-
fore increased transcription of HNF1A, itself a transcrip-
tion activator of AQP9. The increase in AQP9 expression
at the transcription and protein levels led to increase ar-
senic uptake and intracellular concentrations, thereby en-
hancing As2O3-induced cytotoxicity. Blockade of AQP9
by HgCl2 and siRNA knock-down of HNF1A both sup-
pressed azacytidine-induced As2O3 sensitization. Because
azacytidine was removed after pre-treatment, its intrinsic
cytotoxicity did not contribute to the subsequent cytotox-
icity observed with As2O3 treatment. However, in actual
clinical practice, if azacytidine were to be combined with
As2O3 in treating patients, the inherent cytotoxicity of
Chau et al. Journal of Hematology & Oncology  (2015) 8:46 Page 10 of 11azacytidine might further enhance cell-kill and hence the
clinical efficacy of this combination.
One concern of combined azacytidine/As2O3 treat-
ment would be potentiation of arsenic toxicity in other
organs and tissues where AQP9 is also up-regulated.
The liver is a key organ that is affected by As2O3 treat-
ment, particularly when As2O3 is used in the oral formula-
tion due to a first-pass effect. Reassuringly, our preliminary
data in MIHA showed that liver cells already expressed a
high level of AQP9, which was not further increased by
azacytidine treatment. Interestingly, it had been shown
that As2O3-related toxicities, especially in the heart and
liver, were more pronounced in AQP9-nullmice when com-
pared with wild-type mice, as a result of reduced As2O3
clearance [25]. Finally, in a phase I clinical trial examin-
ing As2O3 in combination with another demethylating
drug decitabine in AML, no excessive adverse effects
were reported [21]. Therefore, concomitant azacytidine
and As2O3 treatment might not lead to increased toxicity
in other organs.
The transcription regulation of AQP9 has not been thor-
oughly investigated, and other pharmacological agents
may also activate AQP9 gene through various mechanisms
to enhance the anti-tumor effects of As2O3 [14,15]. Previ-
ous investigations had shown that indirubin and tanshi-
none IIA up-regulated AQP9 expression and augmented
the anti-leukemia effect of As2O3 as present in the
Realgar-Indigo naturalis formula [26]. As AQP9 trans-
membrane protein can be detected and quantified by
fluorochrome-conjugated antibody and flow cytomet-
ric analysis, a high-throughput screening is therefore
feasible in the future to identify compounds that may
up-regulate AQP9 and potentially enhance the thera-
peutic effect of As2O3.
HNF1A is a transcription factor and is highly expressed in
liver, pancreas, and kidneys [27]. It plays a critical role in
transcriptional activation of differentiated hepatocyte-specific
genes critical for liver function such as albumin [28]. Epi-
genetic regulation is involved in tissue-specific expression
of HNF1A, and hypomethylation of the HNF1A gene pro-
moter has been demonstrated in mature hepatocytes and
renal tubular cells [29]. In kidneys, HNF1A regulates the
expression of several organic anion transporters but its
role in aquaporin or aquaglyceroporin expression has not
been reported previously [29]. Furthermore, HNF1A level
has been shown to be associated with differentiation of
hepatocellular carcinoma (HCC) [28]. Given that AQP9
expression may be associated with differentiation of mye-
loid cells [14], it remains to be determined if HNF1A is
also involved in myeloid differentiation. Finally, chronic
exposure of the HCC cell line HepG2 to sub-toxic levels
of arsenic leading to arsenic resistance has been shown
to be associated with down-regulation of HNF1A ex-
pression [30]. This is in agreement with our result, inthat decreasing HNF1A level would result in down-
regulation of AQP9, which led to decreased arsenic entry
into cells, thereby contributing to arsenic resistance.
Conclusions
In conclusion, we have provided proof-of-principle evidence
that a novel strategy of pharmacological up-regulation of
AQP9 might be an approach to increase arsenic sensitivity
in neoplastic cells. Furthermore, given that azacytidine is a
proven treatment for AML, azacytidine, and As2O3 would
be a logical drug combination to be further evaluated for
the treatment of AML in future clinical trials.
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